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Abstract
The treatment of obesity in the pandemic era has become more important than ever. The current situation is condu-
cive to the worsening of disease and the development of new diseases, mainly as a result of compensating negative 
emotions with food. Taking into account the data on the impact of obesity and its complications on the severity of 
the course and the risk of death due to COVID-19, we recommend using the 2016 American Endocrine Society’s 
criteria for the diagnosis of obesity instead of the 1998 WHO criteria. We also recommend diagnosing eating under 
the influence of emotions and the occurrence of eating disturbances, such as compulsive eating syndrome, night 
eating syndrome and food addiction, and complications of obesity, in any person with a BMI ≥ 25 kg/m2.
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Preamble
Obesity has been recognised as a disease by the 
World Health Organisation (WHO) for many years 
and is included in the International Classification of 
Diseases (ICD-10) under number E.66.
The WHO defines obesity as abnormal or exces-
sive accumulation of fat in adipose tissue causing 
deterioration of health. The health consequences of 
obesity depend on the degree of excess body fat, 
its distribution, and the duration of obesity. It is 
a chronic disease without a tendency to spontane-
ously resolve, but with a tendency to relapse. It is 
not a metabolic disease. It should be noted that, it 
is a disease of a complex aetiology in which various 
causative factors  lead  to  eating disturbances that 
cannot be counteracted by physical activity, resulting 
in a positive energy balance and the storage of excess 
energy in adipose tissue. Increasingly, obesity is clas-
sified as a psychosomatic disease.
Overweight is a condition defined as pre-obesity, 
in which the degree of excess fat that does not yet 
meet the criteria for diagnosing obesity [1].
Contrary to popular belief, obesity is not the fault 
of the patient. Blaming the patient for being ill is 
not ethical and leads to a lack of effective treatment, 
and as a consequence the disease progresses, its com-
plications develop, the quality of life deteriorates, 
disability develops, and life expectancy shortens [2].
The contemporary approach to making therapeu-
tic decisions is based on the principles of biomedical 
ethics published in the late 1970s, including patient 
autonomy, benefits and safety, and fairness.
How the autonomy of a patient with obesity is 
violated:
• Lack of access to an appropriate obesity treatment 
system and reimbursement of drugs supporting 
its treatment, as well as specialist medical advice, 
dietary advice, and psychotherapy.
• The archaic and pejorative view that obesity is 
the result of a lack of discipline and self-control, 
also among healthcare workers. This stigmatises 
obese patients, influences their patient judgment, 
interpersonal behaviour, and treatment decisions.
• Patients’ negative experiences from previous con-
tacts with healthcare professionals lead to stress 
and avoidance of seeking care, distrust of doc-
tors, and non-compliance with their recommen-
dations.
It should be emphasised that stigma and preju-
dices restricting access to appropriate treatment are 
an unacceptable violation of the patient’s right to 
autonomy.
Ethical benefit and security are based on the prin-
ciple “Do No Harm First”. In this context, there 
are two dimensions: individual and social. In the 
individual dimension, the ethical aspect includes not 
recommending methods of diagnosing and treating 
obesity, the effectiveness and safety of which have 
been scientifically proven, and not informing the 
patient about all methods that can and should be 
applied to him/her. However, in social terms, there 
is a tendency to blame obese patients for the fact that 
their excess body mass results in a cost to other mem-
bers of society. Interestingly, patients with complica-
tions of obesity are not blamed for the fact that they 
suffer from them, which creates a paradox, e.g. you 
are guilty that you suffer from obesity, but it is not 
your fault that you suffer from one of its most com-
mon complications: type 2 diabetes. It is unethical 
to blame obese patients for exposing other members 
of society to costs because they are not provided with 
appropriate medical care in accordance with current 
knowledge.
The approach to treatment should be individualised and should not be limited to nutritional and physical activity 
education alone. Each patient should be offered appropriately selected pharmacotherapy, and, if necessary, also psy-
chotherapy. The first-line drug should be a combined preparation containing naltrexone and bupropion (Mysimba®). 
Liraglutide in a dose of 3 mg (Saxenda®) should be considered as a second-line drug in a situation where eating under 
the influence of emotions is excluded (reaching for food in situations of experiencing negative and positive emotions 
and boredom, eating disturbances: compulsive eating syndrome, night eating syndrome, and food addiction) and 
depressed mood or there are permanent contraindications to the use of the first-line drug.
It is unethical not to treat obesity or refer the patient to another doctor for treatment. The use of telemedicine tools 
can facilitate work in therapeutic teams (doctor, dietitian, psychotherapist), as well as improve patient compliance 
with pharmacotherapy and changes in eating habits and the level of physical activity recommendations.
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Justice in terms of etical includes resource con-
straint, respect for individual rights, and adherence 
to established laws.
Patients diagnosed with obesity experience inequali-
ties in health and limitations in self-determination not 
only because of the underlying disease, but also when 
they develop other chronic diseases due to the lack 
of equipment and negative attitudes of medical staff 
caused by stereotypical thinking, and lack of knowl-
edge in the field of obesity treatment and inability to 
refer the patient to an obesity treatment centre [2, 3].
The principles of an ethical approach to obesity, 
developed by the American Society of Gynaecolo-
gists and Obstetricians, show that negative attitudes 
towards obese patients occur even among doctors 
specialising in obesity treatment. The conducted 
studies show that the reasons for this negative at-
titude are very different from the fact that the doc-
tor also suffers from obesity to the aforementioned 
blaming patients for their disease, perceiving them as 
problematic and time-wasting. It has been observed 
that this results in a disturbance of the doctor–pa-
tient relationship because doctors show less empathy 
towards obese patients, are less likely to engage in 
counselling and patient-centred care, and paradoxi-
cally spend less time on them. Such an attitude of 
a doctor may delay the proper diagnosis of the cause 
of obesity and initiate effective treatment. Moreover, 
a patient who has experienced prejudice or stigmati-
sation may avoid treatment not only of obesity, but 
also of its complications. It has been shown, inter 
alia, that neoplasms in obese patients are diagnosed 
at a high degree of advancement because they appear 
not much less frequently for screening [2, 4].
Not only from a medical but also ethical point 
of view, every doctor should perceive obesity as 
a chronic disease with a complex etiology that re-
quires treatment. A patient with obesity should be 
treated with respect, and his/her illness should not be 
a source of shame and self-blame. A physician should 
use appropriate medical vocabulary in relation to an 
obese patient, show empathy towards him/her and 
give advice appropriate to his/her situation, as well 
as implement all possible therapeutic procedures, 
including pharmacotherapy and psychotherapy [2]. 
The principle of person-centred care should be the 
norm in the approach to obese patients [5].
Why should obesity be treated  
during a pandemic?
In Poland, nearly 8 million adults suffer from obesity 
diagnosed on the basis of the World Health Organi-
sation criteria, and overweight is diagnosed in almost 
19 million. Due to the lack of reliable data, estimat-
ing the incidence of all chronic obesity complications 
is extremely difficult. Numerous data confirm that 
the causal treatment of obesity complications is its 
effective treatment with the use of all scientifically 
proven methods, tailored to the individual patient’s 
needs.
The COVID-19 pandemic has proven that the 
current approach, focused mainly on symptomatic 
treatment of obesity complications, does not bring 
the intended results if the patient becomes infected. 
The inequality in health experienced by obese pa-
tients has made them the most vulnerable to severe 
COVID-19 infection and death thereof.
Data from China, Italy, and the USA showed that 
obese patients infected with COVID-19 had a lon-
ger duration of infection and more often required 
intensive medical supervision, including intubation 
and mechanical ventilation. Moreover, obesity and 
its complications were independent risk factors for 
hospitalisation and death of the infected [6–9]. It 
should also be noted that data from a study con-
ducted in New York showed that obesity and its 
complications caused severe COVID-19 infection 
and increased the risk of death also among children 
and adolescents [10].
Overweight in patients with SARS-COV-2 infec-
tion increased the risk of developing severe pneumo-
nia by 86%, and obesity by 142% [11]. What are 
the reasons for this? Obese patients have decreased 
immunity (chronic systemic inflammatory reaction, 
increased activation of the hypothalamic-pituitary-
adrenal system, low physical activity), they often 
have obese hypoventilation syndrome (reduced chest 
volume — disorders of ventilation and perfusion), 
left ventricular hypertrophy, and sometimes heart 
failure.
The major complications of obesity also increase 
the risk of death from COVID-19 (hypertension by 
6%, type 2 diabetes by 7.3%, cardiovascular disease 
by 10.5%, chronic lung disease by 6.3%, and cancer 
by 5.6%) [12].
It should be emphasised that quarantine in the 
long term due to exposure to stress may increase 
people’s susceptibility to obesity development, a risk 
factor for severe COVID-19 infection [13, 14]. It 
should also be added that the same stressors may 
have an impact on people not subject to forced quar-
antine. Food is an easily accessible “stepping stone” 
from problems; therefore, we are dealing with an in-
crease in the percentage of people who eat under the 
influence of emotions and those who meet the crite-
ria for the diagnosis of eating disturbances (compul-
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sive eating syndrome, night eating syndrome, food 
addiction) and those with worsening of pre-existing 
disturbances.
Factors that cause anxiety and sadness at present 
include the following: adaptation to new functioning 
conditions, the possibility of infection, illness of rela-
tives — especially the elderly, fear of creating a threat 
to others, uncertain future in the health and social 
dimension (it is not known when the pandemic will 
end and when life will return to normal, it is not 
known whether the pandemic will not return in the 
future, fear of what the world will look like after the 
pandemic, how much we will have to change our 
lifestyle, our habits, and re-evaluate our dreams, fear 
of worsening economic situation, loss of job, and col-
lapse financial), social isolation and increasing family 
conflicts, organisational problems related to remote 
work and remote learning, limitations in relieving 
stress outside the home (fear of using fitness clubs, 
cinemas, theatres, and other entertainment venues, 
and traveling). Additionally, there is a significant 
deficit of positive stimuli.
A separate factor influencing weight gain during 
the pandemic is the reduction in physical activity due 
to the introduced restrictions and quarantine.
The reward system and the regulation  
of food intake
The regulation of food intake is a complex process 
and is not limited to satiety and hunger, which are 
biological signals controlled by the hypothalamus. 
Hunger is a physiological feeling of the state of 
higher organisms related to a lack of food. It is also 
a contributing impulse to food intake and gaining 
behaviour. However, satiety inhibits this impulse.
An important role in human food intake is played 
by the sensation of appetite, which causes the search 
for a specific food not to satisfy hunger but to feel 
the pleasure of eating it. Appetite is driven by emo-
tions and is independent of the feeling of satiety. 
The reward system is responsible for the feeling of 
appetite [15, 16].
Even in people with normal body mass, stress (the 
body’s reaction to events that disrupt its homeosta-
sis — stressors related to experiencing both nega-
tive and positive emotions that exceed our ability to 
cope effectively) and the associated activation of the 
hypothalamus-pituitary-adrenal gland axis increases 
the release of cortisol, reduces the sensitivity of the 
hypothalamus to the action of leptin, and enhances 
the influence of the reward system, which is respon-
sible for food intake related not to biological need 
but to pleasure [17]. Activation of the reward system, 
including its parts such as the nucleus accumbent, 
increases the tendency to eat high-energy food high 
in sugar, fat, and sodium [18]. Stress can lead to eat-
ing more food, and with a higher propensity to eat 
high-energy foods. In addition, stress reduces the 
tendency to exercise and interfere with sleep. The 
mechanism of treating food as a reward or consola-
tion arises in infancy or may be established later in 
life. Overeating can be a way to reduce anxiety and 
frustration. Many people eat food when the stress 
factor is unclear and causes a predominant feeling of 
anxiety. Eating becomes a way to regain self-control 
over the level of feeling emotions.
Stimulation of dopamine neurons in the ventral 
tegmental area causes the release of dopamine in the 
nucleus accumbens. Activation of dopamine recep-
tors causes a feeling of conscious pleasure (prefrontal 
cortex) and motor activity related to the search for 
reward (basal ganglia). The hippocampus (memory) 
and amygdala (emotions) are also activated. The 
subjective feeling of pleasure is proportional to the 
amount of dopamine released from the nerve end-
ings in the nucleus accumbens. Tasty food increases 
dopamine levels by 50%. It can be concluded that 
reducing dopamine secretion in the structures of the 
reward system causes the desire/impulse to obtain 
pleasure, and endogenous opioids increase the feeling 
of pleasure from, for example, eating [19].
Diagnosis of obesity  
— should the new criteria be used?
The 1998 diagnostic criteria for overweight and 
obesity are based solely on body mass index (BMI) 
values and do not take into account the amount or 
distribution of adipose tissue in the body or their im-
pact on the patient’s health [1]. Data on the impact 
of overweight and obesity and their complications on 
the severity of the course and the risk of death from 
COVID-19 indicate that it is time to revise these ar-
chaic criteria and adopt algorithms that can be used 
in any doctor’s office, but taking into account the 
patient’s general health. These conditions are met by 
the criteria proposed in 2016 by the American En-
docrine Societies. On the basis of which we recognise 
the following:
• overweight degree 0 — BMI 25.0–29.9 kg/m2 
and without complications such as the follow-
ing: pre-diabetes, type 2 diabetes, dyslipidaemia, 
arterial hypertension, cardiovascular disease, non-
alcoholic fatty liver disease, polycystic ovary syn-
drome, female infertility, male hypogonadism, 
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asthma, sleep apnoea syndrome, hypoventilation 
syndrome, gastroesophageal reflux disease, stress 
urinary incontinence, osteoarthritis, and depres-
sion,
• obesity degree 0 — BMI ≥ 30 kg/m2 and without 
the above-mentioned complications,
• first-degree obesity — BMI ≥ 25 kg/m2 and ≥ 1 
mild or moderate complication,
• second-degree obesity — BMI ≥ 25 kg/m2 and ≥ 1 
severe complication [20].
These criteria allow for a much earlier diagnosis 
of obesity and initiation of treatment, which may 
significantly improve health or prevent the develop-
ment of complications. Therefore, we recommend 
using them.
However, these criteria also do not include the 
diagnosis of the root cause of the positive energy 
balance. Proper diagnosis of the cause of obesity de-
velopment allows the selection of adequate treatment 
methods and increases its effectiveness. Most of the 
failures in the treatment of obesity are the result of 
the wrong approach that proper nutritional educa-
tion and the strong will of the patient will suffice. 
The lack of understanding of the role of emotions in 
influencing food intake and the fact that disorders 
in the functioning of the reward system make the 
patient “willing but unable” frustrate both the doc-
tor and the patient, which results in discouragement 
from undertaking obesity treatment. The view that 
eating disorders should be diagnosed by a psychiatrist 
is incorrect because screening is performed using 
simple diagnostic tools, such as diagnostic criteria:
• compulsive eating syndrome: repeated episodes 
of uninhibited eating at least once a week for 
three months and at least three of the following 
symptoms: eating much faster than normal, eat-
ing until you feel uncomfortably full, eating large 
portions of food without feeling physically hun-
gry, eating alone due to shame/embarrassment in 
eating, feeling disgusted with oneself, depression 
or guilt after overeating, as well as a pronounced 
suffering about the way of eating and the lack of 
compensatory activities related to it (induction of 
vomiting, use of diuretics, significant increase in 
physical activity) [21];
• night eating syndrome: eating ≥ 25% of one’s 
daily amount of food after the evening meal or 
at night with consciousness at least twice a week 
for at least three months and at least three of the 
following symptoms: skipping breakfast due to 
lack of appetite at least four times a week, a strong 
need to eat between the evening meal and falling 
asleep or at night, difficulty falling asleep or wak-
ing up from sleep at least four nights a week, the 
conviction that food is needed as a condition for 
starting or returning to sleep, frequent worsen-
ing of mood in the evening, as well as significant 
suffering or deterioration in functioning, and the 
lack of criteria for mental bulimia and seizure 
syndrome overeating [22];
• food addiction: eating more, or more than in-
tended, persistent desire to eat or unsuccessful 
attempts to limit food consumption, devoting 
a large amount of time to eating activities, ne-
glecting social duties and activities, eating food 
despite negative physical, mental, and social con-
sequences, limiting or abandoning important so-
cial, professional, or recreational activities due to 
food consumption, and the occurrence of with-
drawal syndrome [21].
Any doctor should treat eating disorders in cooper-
ation with a psychotherapist. However, it should be re-
membered that eating under the influence of emotions 
does not have to meet the criteria for the diagnosis of 
eating disorders, and it occurs in an even greater group 
of obese patients than the disorders discussed above. 
Therefore, patients should be asked about eating un-
der stress, after a stressful situation, in conditions of 
boredom, or even strong positive emotions.
Obesity treatment  
— who, when, and how?
The ideal situation would be if an obese patient 
could be referred to a specialist centre, where he/she 
would be looked after by an obesitologist in coopera-
tion with a dietitian, psychologist, and physiothera-
pist. Because there is no coordinated system of obe-
sity treatment in Poland, and its treatment is among 
the duties of a family doctor and specialist doctors 
caring for patients diagnosed with obesity complica-
tions, it is these groups of doctors who are obliged to 
diagnose and treat this disease. If the doctor is unable 
or unwilling to treat obesity, after diagnosing it, he/ 
/she should refer the patient to another doctor who 
will take care of the patient. We suggest that patients 
be referred to doctors who have obtained certificates 
of the Polish Association for the Study of Obesity. 
The list of such people is available on the websites 
ptbo.edu.pl or certyfikacjaptbo.pl. [23]. It is unethi-
cal not to diagnose and treat obesity or to refer the 
patient to another physician to treat obesity. Obesity 
is a disease, and referring a patient to a dietitian as 
the only action without implementing all the neces-
sary therapeutic methods is also an unethical action.
It should be emphasised that four out of five 
medications registered in the USA for the treatment 
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of obesity and two out of every three approved in 
Europe act in the central nervous system. The only 
drug that acts locally in the gastrointestinal tract is 
orlistat, a drug of marginal importance in the phar-
macological treatment of obesity. Drugs influencing 
food intake have a pharmacological effect in the 
CNS, because these are the centres responsible for 
the feeling of satiety, hunger, and appetite. However, 
this does not provide sufficient justification for the 
drugs registered to support obesity treatment to be 
prescribed only by a psychiatrist, and even less so that 
only a psychiatrist can diagnose eating disturbances
Obesity is a progressive disease, and the develop-
ment of its complications depends on the distribu-
tion of adipose tissue, the stage of the disease, and its 
duration. In order to prevent the progression of the 
disease and the development of complications, treat-
ment of obesity should be started as early as possible 
at the stage of overweight degree 0. It should also be 
undertaken at any other stage of the disease, without 
waiting for the development of complications.
The overarching goal of obesity treatment is to 
inhibit the progression of the disease, avoid recur-
rences, prevent the development of complications 
caused by excess body fat or reduce their severity, 
improve the overall health and quality of life of the 
patient, and extend their life. To achieve this goal, 
different percentages of body mass reduction from 
baseline may be needed in different patients [23].
In order to prevent obesity complications, the 
initial goal is a reduction of 5–10% of the initial 
body mass over a 3–6-month period, then the same 
maintenance period, followed by another 5–10% 
reduction in body mass. The main goal in patients 
without obesity complications is to reduce the sever-
ity of the disease by one degree. On the other hand, 
in patients with complications, the overriding goal is 
to achieve a weight reduction that will significantly 
improve the control of this complication, the possi-
bility of reducing the number or doses of drugs used 
due to the complication or discontinuing their use, 
and in some cases achieving remission in terms of the 
complication [23].
In the treatment of obesity, unlike slimming, the 
goal is not to lose weight quickly and significantly, 
but to reduce it slowly and over the long term, which 
will improve health and quality of life, and increase 
life expectancy. Therefore, the methods used in the 
treatment of obesity, including pharmacotherapy, are 
to cause a slow loss of body mass. This should be 
carefully explained to the patient, because the result 
may not match their expectations, which must be 
verified, and the new goal must be accepted by the 
patient. The goal assigned to the patient must be 
specific, measurable, acceptable, realistic, and timely 
(SMART). On the way to the final goal, it is neces-
sary to set sub-goals and short-term goals ranging 
from three to six months [23].
As already mentioned, the selection of obesity 
treatment methods must be individualised, taking 
into account, first of all, the root cause of a disturbed 
energy balance. It should be remembered that this 
treatment is a long-term process.
In the treatment of overweight and obesity, the 
doctor should follow the 5A rule:
• ASK — explaining to the patient the essence of 
the disease and its consequences and assessing 
his/her readiness to change,
• ASSESS — assessment of health, causes of weight 
gain, and the occurrence of complications caused 
by excess fat in the body,
• ADVICE — presenting treatment options that 
can be applied to a specific patient,
• AGREE — obtaining the patient’s consent for the 
proposed therapeutic goal and treatment plan,
• ASSIST — supporting the patient in the thera-
peutic process [24].
The basis of  treatment  of  overweight  and 
obesity is to obtain a negative energy balance by 
changing eating habits and increasing physical ac-
tivity. However, it should be remembered that in 
patients with an emotional background of increased 
food consumption, nutritional education itself may 
be counterproductive; we should remember that 
such a patient really wants to do this but is unable 
to. Their brain calls to eat and the fact that he/she 
does not follow the recommendations is not his/her 
fault. The role of the doctor is to help such patients 
through the use of appropriate pharmacotherapy, in 
some cases also prescribing psychotherapy.
Surgical treatment in patients with an emotional 
background of increased food consumption should 
be recommended with caution, and pharmacologi-
cal and psychological support should be taken into 
account both during the preparation for surgery and 
after its performance [25].
Individual selection of pharmacotherapy 
based on the mechanisms of drug 
action and the causes of obesity 
— monotherapy positioning, use of 
polytherapy
Currently, there are three drugs available in Poland 
to support the treatment of overweight and obesity:
• orlistat (gastrointestinal lipase inhibitor) is used 
only in the group of patients who prefer fat-
Magdalena Olszanecka-Glinianowicz et al. Treatment of overweight and obesity during and after a pandemic — new guidelines for doctors
99www.ah.viamedica.pl
ty foods and have no problems controlling the 
amount of food consumed (it does not affect the 
feeling of satiety and appetite). In view of current 
knowledge on the importance of emotions in the 
regulation of food intake, this drug is of marginal 
importance and therefore has not been included 
in the current guidelines;
• a combination medicinal product containing two 
active substances: bupropion hydrochloride and 
naltrexone hydrochloride, reduces food intake by 
increasing satiety and inhibiting eating under the 
influence of emotions (appetite). This drug acts 
synergistically on the neurons of the arcuate nu-
cleus of the hypothalamus. The active substances 
contained in the drug increase the secretion of 
proopiomelanocortin of the a-melanotropin 
precursor (a-MSH) (bupropion — stimulation 
of the feeling of satiety) and prolong its release 
by blocking the mi opioid receptor (naltrexone 
— prolonging the feeling of satiety). Moreover, 
bupropion, by inhibiting dopamine reuptake in 
the synapses of the mesolimbic reward system, 
and naltrexone, by blocking opioid receptors, re-
duce appetite. Thus, this drug acts on both the 
biological and emotional mechanisms of food 
intake, which facilitates the patient’s implemen-
tation of recommendations regarding changes in 
eating habits [15, 26];
• liraglutide, a long-acting GLP-1 receptor ana-
logue, increases the glucose-dependent insulin se-
cretion from pancreatic b-cells (1.8 mg/day used 
in the treatment of type 2 diabetes). Moreover, 
liraglutide, acting on the centres of satiety and 
hunger in the hypothalamus, stimulates the feel-
ing of fullness and inhibits the feeling of hunger. 
This drug does not affect food intake related to 
emotions; that is the appetite [27].
In accordance with the recommendations of 
the American Endocrine Associations, short-term 
(3–6 months) pharmacological treatment of obesity 
has not shown long-term health benefits in clinical 
trials and is not recommended. It is also recom-
mended that chronic use of pharmacotherapy be 
considered due to the chronic nature of the disease. 
The selection of pharmacotherapy should be indi-
vidualised [20]. The current guidelines also recom-
mend this approach to the use of pharmacotherapy 
supporting the treatment of obesity.
We recommend that pharmacotherapy be offered 
to everyone who is overweight or obese if there are 
no contraindications to its use.
It is worth remembering that WHO diagnostic 
criteria based solely on BMI values do not properly 
reflect the stage of the disease. The new diagnostic 
criteria of the American Endocrine Societies of 2016 
also take into account the occurrence of complica-
tions caused by excess fat in the body [20]. In each 
case of complications caused by excess body fat, in 
the treatment of which the causative treatment is to 
achieve weight loss, and in each case of eating under 
the influence of emotions or low mood, especially if 
it is accompanied by low self-esteem, the simultane-
ous implementation of lifestyle changes and pharma-
cotherapy should be considered.
Individual selection of pharmacotherapy should 
be based on the identified an etiological factors that 
led to the development of the disease. As already 
mentioned, the causal treatment of obesity is the 
basis for the effective treatment of its complications. 
The archaic approach of putting the complications 
of obesity rather than its causes in the selection of 
pharmacotherapy should be abandoned. Failures in 
obesity treatment are the result of this approach. 
Current knowledge indicates that in the selection of 
pharmacotherapy of complications, obesity should 
be taken into account as a cause, and in the selection 
of pharmacotherapy of obesity, factors causing a pos-
itive energy balance should be taken into account.
Based on the data from available studies on the 
aetiology of the disease, as well as efficacy and safety, 
we recommend the following criteria for selecting 
pharmacotherapy:
1. Due to its mechanism of action, efficacy, and 
safety, the drug considered as a first-line drug 
should be a combined preparation containing 
bupropion and naltrexone (Mysimba®).
2. Liraglutide in a dose of 3 mg (Saxenda®) should 
be considered as a second-line drug in a situation 
where eating under the influence  of  emotions 
is  excluded (reaching for food in situations of 
experiencing negative and positive emotions and 
boredom, eating disorders: compulsive eating 
syndrome, night-time syndrome, addictive eat-
ing) and depressed mood or there are persistent 
contraindications to the use of the first-line drug.
3. The use of polytherapy with a combination prod-
uct of bupropion and naltrexone and liraglutide 
should be considered in patients with impaired 
carbohydrate metabolism with associated emo-
tional eating. In this case, the dose of liraglutide 
used should be selected individually (1.8 mg Vic-
toz® or 3.0 mg Saxenda®) depending on whether 
only type 2 diabetes or obesity is considered as 
the indication for the use of liraglutide.
4. Liraglutide doses lower than 3.0 mg daily and 
other active substances not approved for the treat-
ment of overweight and obesity in monotherapy 
should not be recommended in monotherapy.
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Justification of the above 
recommendations
1. Emotional eating is the most common cause of 
noncompliance with the recommendations for 
changing eating habits; the patient wants to but 
cannot. The use of pharmacotherapy, which does 
not affect the reward system, does not bring the 
expected results, increases frustration, and pro-
motes eating. Not all emotional eating can be 
diagnosed as an eating disturbance. Emotions 
triggering eating can vary in nature, including 
tension and fear, but also boredom. The preva-
lence of eating disorders among obese patients 
is estimated at 40–70%, but this can be greatly 
underestimated because they are rarely diagnosed.
2. Both drugs act centrally, but only the combina-
tion of bupropion with naltrexone, by acting on 
the reward system, suppresses appetite and thus 
eating under the influence of emotions, addi-
tionally improves the mood [28]. Isolated studies 
suggesting an effect of liraglutide on the reward 
system come from animal studies. In a study us-
ing functional magnetic resonance imaging in 
a group of 20 patients treated for five weeks with 
liraglutide 5.0 mg or placebo no differences in 
the response of reward system areas to food im-
ages were found between the study groups [29]. 
The choice of the combination of bupropion and 
naltrexone as the first-line drug proposed in this 
document and liraglutide as the second-line drug 
is not a common recommendation in many ex-
isting documents and expert group positions. It 
may therefore arouse polemics on the part of 
other experts. However, this position proposes 
such a prioritization of these drugs also due to 
the greater acceptance of the form of oral treat-
ment (first-line treatment) than of subcutaneous 
injections (second-line treatment) and the fact 
that obese patients more often require therapy af-
fecting the function of the reward system, which 
helps in dealing with situations where emotions 
are the cause of consuming excess energy. In ad-
dition, experts suggested similar solutions (first-
line drug — Mysimba®, second-line drug — Sax-
enda®) recently  adopted  in the current treat-
ment and reimbursement regimens in Norway 
and Denmark. Perhaps, the emergence of other 
effective oral medications for the treatment of 
obesity, as well as new research, will require our 
opinion to change in the future.
3. The combination of bupropion with naltrexone 
has a better safety profile. A comparative analysis 
showed that the number needed to harm (or 
the number of people in treatment during the 
year who experience side effects) is 1 in 17 with 
bupropion and naltrexone in combination and 1 
in 4 with liraglutide. Therefore, side effects oc-
cur more than four times often during the use of 
liraglutide [30].
4. Efficacy: a total of 12,868 patients  participated 
in the clinical trials of bupropion and naltrex-
one combination COR III phase and LIGHT IV 
phase, with a weight loss of at least 5% at base-
line in 53–80% (depending on the study) for 56 
weeks, and 10% in 26–55% [31–35]. In  contrast, 
the phase III SCALE trials, which involved a total 
of 5358 patients for 56 weeks, achieved a weight 
loss of at least 5% at baseline in 63.2% of patients 
treated with 3.0 mg, and 10% in 33.1% [36–39].
5. The cardioprotective effect of liraglutide and the 
reduction of the risk of death from cardiovascular 
causes were observed only in the group of patients 
with type 2 diabetes (LEADER study) [40]; there 
were no such data in other obesity groups. The 
LEADER study used the approved dose of liraglu-
tide  for  diabetes (1.8 mg/day), not the approved 
obesity dose (3.0 mg). The results of these studies 
cannot be extrapolated to the entire population, 
nor the fact that liraglutide prolongs life expec-
tancy. The LEADER study included patients with 
known cardiovascular disease and people  with 
cardiovascular  risk  factors.  Subgroup analysis 
suggests that the cardiovascular benefit of liraglu-
tide was primarily in the subgroup of patients with 
known cardiovascular diseases in which specific 
cardiovascular benefits were previously seen. In 
contrast, a study to evaluate lixisenatide in acute 
coronary syndrome (ELIXA) showed no cardio-
vascular benefit from its use in patients with type 
2 diabetes and recent acute coronary syndrome. In 
the ELIXA study, no such group differences with 
regard to cardiovascular medications were found. 
Perhaps some of the cardiovascular benefits that 
were observed in the LEADER study were due 
to differences in standard of care rather than the 
use of liraglutide. Multivariate analyses should be 
carried out, which would at least partially explain 
these doubts [41]. Post hoc calculations, which 
are based on the actual sample size, indicate that 
the sample power for the observed superiority 
was 75.5%, which is well below the previously 
planned 90% power for non-worse. Thus, this 
lack of power raises concerns about the type I error 
of superiority [42]. The reduction in HbA1c levels 
with liraglutide was modest and other factors, 
such as weight loss, may have contributed to the 
benefits seen with liraglutide [43]. A high propor-
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tion of patients enrolled in these studies had previ-
ously experienced a CVD adverse event; therefore, 
this therapy is assessed mainly as a secondary pre-
vention of subsequent CVD events. This cannot 
be fully translated into primary prevention. These 
studies provide reassuring evidence that the new 
glucose  lowering drugs do not adversely affect 
CVD events, and some of these drugs may reduce 
their risk [44]. In the LEADER study, the primary 
endpoint incidence was 13.0% lower with lira-
glutide than with placebo. There was also a 22% 
lower CVD death rate and a 15% reduction in all-
cause deaths. The number of patients needed to 
treat (NNT) to prevent one cardiovascular event 
in three years was 66 and to prevent death from 
any cause was 98 [45]. It has also been shown that 
the benefits of liraglutide appear to be limited to 
a predetermined subgroup of people with known 
cardiovascular disease. Therefore, the conclusions 
and implications of the LEADER study are cur-
rently limited to the group with type 2 diabetes at 
high cardiovascular risk [46]. Experts emphasize 
that our comments and doubts concern only the 
unauthorized extrapolation of the LEADER study 
results to the obese patient population. However, 
they do not undermine the importance of this 
study for contemporary diabetology and current 
antidiabetic treatment algorithms, especially in 
patients at high cardiovascular risk.
6. There are no comparative studies assessing the 
time it takes for the drugs to take effect.
The use of telemedicine techniques  
in the treatment of obesity  
in the pandemic era and in the future
Currently, in providing remote advice, telephone 
contact or instant messaging is most often used. 
However, more and more often telemedicine ap-
plications using artificial intelligence algorithms are 
used. Such solutions are already used in psychiatry. 
Psychiatrists were also the first to provide recom-
mendations for tele-visiting during a pandemic. Ac-
cording to these recommendations, the conversation 
with the patient should begin with the assessment 
of the patient’s anxiety related to the epidemic, reas-
suring him/her and supporting him/her in drawing 
appropriate conclusions and correcting the informa-
tion chaos he/she was subjected to. After the patient 
has calmed down, move on to his/her current health 
problem. Questions should not be left unanswered, 
and the patient should be able to contact remotely if 
necessary [47].
The sanctioning of the place of tele-visiting in the 
NHF system allowed help to be provided for many 
patients during the closure of health care facilities 
due to the pandemic, it also facilitated the introduc-
tion of e-prescriptions.
The combination of traditional counselling and 
televisiting can be an effective tool for diagnosing 
and treating obesity when there is no time at the 
clinic. Moreover, the inclusion of telemedicine in 
the care of obese patients may contribute to the 
improvement of the doctor-patient relationship and 
the patient’s compliance with the recommendations, 
including those related to pharmacotherapy. Prior  to 
March  2020,  GPs  provided  sporadic  telephone 
consultations. Before 2019, this type of advice was 
not sanctioned by the National Health Fund. Medi-
cal tele-visit was introduced by the Regulation of the 
Minister of Health of October 31, 2019, amending 
the regulation on guaranteed benefits in the field of 
primary health care Journal of Laws 2019 item 2120. 
The provisions came into force on November 5, 
2019. The regulation specifies the issue of providing 
services in outpatient conditions, but also as part of 
night health care, indicating that remote assistance 
is possible via teleinformation systems or telephone 
communication. Thanks to this, the patient has the 
right to tele-visit.
From January 2020, at least once a year, the family 
doctor should take anthropometric measurements 
and assess the nicotine status of each patient re-
porting to the primary health care practice (new 
requirement of the National Health Fund — Order 
of the President of the National Health Fund No. 
177/2019 / DSOZ).
Currently, in 2020, the National Health Fund 
additionally finances the care of patients chronically 
suffering from diabetes, cardiovascular diseases, or 
thyroid gland conditions. Most of these patients are 
also obese. It is advisable that obesity should also 
be included as a chronic disease in the list of causes 
of medical consultations qualifying for additional 
financing by the National Health Fund. Until the 
new regulations are in place in the GP surgery, advice 
on obesity may be part of the follow-up advice on 
chronic diseases. A family doctor who has appropri-
ate knowledge about obesity and drugs supporting 
its treatment has an ethical duty to treat obesity and 
propose pharmacotherapy to the patient. In order to 
increase the knowledge of doctors, current guidelines 
have been developed.
During the pandemic, tele-visit were also used and 
reimbursed in specialist counselling.
Telemedicine in the form of the use of medical ap-
plications in the treatment of obesity is a new formu-
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la for supporting behavioural and pharmacological 
therapy. These applications can support the doctor 
both in the diagnostic process and in making ther-
apeutic decisions, and support treatment through 
various forms of increasing therapeutic  adherence, 
digital forms of treatment, and monitoring the pa-
tient’s condition between meetings or tele-meetings 
with the doctor. Contact between a doctor, dietitian, 
or psychologist with the patient should be in the 
form of video-visits, enabling the establishment of 
eye contact, assessment of the patient’s facial expres-
sions and pantomimics as well as establishing contact 
and a therapeutic relationship.
Telemedicine applications can be particularly use-
ful in increasing therapeutic adherence. Low ther-
apeutic adherence of obesity patients is the cause 
of incomplete treatment effectiveness, side effects 
of drugs, and in the long term, somatic and psy-
chological complications of obesity, hospitalisation, 
and increased treatment costs. The reason for low 
therapeutic adherence is usually false and inadequate 
beliefs about obesity, rationalising and contradicting 
it, beliefs about the ineffectiveness of drugs or the 
presence of their side effects, or the lack of patient 
resources (e.g. lack of economic resources to buy 
drugs or forgetting to take a drug). All these reasons 
should be taken into account when creating remote 
telemedicine obesity treatment algorithms.
Telemedicine applications use various methods to 
support therapeutic adherence that can be used in 
the treatment of obese patients. Those are:
• reminders in the form of text messages and smart-
phone notifications,
• video education on the disease and drugs,
• obesity support groups in communities in the 
Internet environment,
• point systems that strengthen the habit of taking 
medication,
• video meetings with a doctor, psychotherapist, 
or dietician.
Improving drug compliance  and  the  effective-
ness of obesity treatment using telemedicine tools 
requires a comprehensive approach to the entire 
treatment process, not only focusing on therapeu-
tic adherence. In constructing telemedicine obesity 
therapy, it is advisable to take into account the fol-
lowing recommendations:
Creation and development of user-friendly tele-
medicine applications enabling full visual-auditory 
and safe video-connection with the patient.
Creation, research, and popularisation of tele-
medicine applications for effective stress reduction 
as a supporting method in the treatment of obesity. 
Medical applications can thus offer an alternative 
strategy to deal with negative emotions in relation 
to food. In reduction of stress in patients treated 
for obesity can use virtual reality, augmented real-
ity, breathing training, therapeutic games, and pro-
health musical frequencies.
Such applications offer great hope for more effec-
tive obesity treatment in the near future.
Summary
Treating obesity in the pandemic era is more impor-
tant than ever. The current situation is conducive to 
the development of new diseases and disease worsen-
ing, mainly as a result of compensating for negative 
emotions by eating. Taking into account the data on 
the impact of obesity and its complications on the 
severity of the course and the risk of death due to 
COVID-19, we recommend using the 2016 Ameri-
can Endocrine Society’s criteria for the diagnosis of 
obesity instead of the 1998 WHO criteria. We also 
recommend diagnosis of eating under the influence 
of emotions and the occurrence of eating distur-
bances such as compulsive eating syndrome, night 
eating syndrome and addictive eating, and the oc-
currence of obesity complications. It is also advisable 
to diagnose family members towards overweight and 
obesity and to involve them in helping the patient.
The approach to treatment should be individu-
alised and should not be limited to nutritional and 
physical activity education. Each patient should be 
offered appropriately selected pharmacotherapy, and, 
if necessary, also psychotherapy. The first-line drug 
should be a combined preparation containing nal-
trexone and bupropion (Mysimba®). Liraglutide in 
a dose of 3 mg (Saxenda®) should be considered as 
a second-line drug in a situation where eating un-
der the influence of emotions is excluded (reaching 
for food in situations of experiencing negative and 
positive emotions and boredom, eating disturbances: 
compulsive eating syndrome, night eating syndrome 
and addictive eating), depressed mood, or there are 
persistent contraindications to the use of the first-
line drug.
It is unethical not to treat obesity or refer the pa-
tient to another doctor who will treat it. The use of 
telemedicine tools can facilitate work in therapeutic 
teams (doctor, dietitian, psychotherapist), as well as 
improve patient compliance with pharmacotherapy 
recommendations and changes in eating habits and 
the level of physical activity. To facilitate the applica-
tion of the above guidelines in practice, an algorithm 
for the diagnosis and treatment of obesity using tele-
medicine techniques has been developed (Fig. 1). 
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Figure 1. Algorithm for diagnosing and treating obesity using telemedicine techniques
ź measure body mass and height, calculate BMI, measure waist 
2circumference – if the BMI is ≥ 25 kg/m , take a history 
of obesity complications, or, if necessary, order a diagnosis 
(their list is attached to the algorithm)
ź diagnose eating under the inuence of emotions (see the questions 
in the appendix) and eating disorders (diagnostic criteria in the 
appendix to the algorithm) and depressed mood (Beck’s scale)
ź make a diagnosis based on the recommendations 
of the American Endocrine Societies
ź obtain the patient’s acceptance as to the proposed therapeutic 
methods
ź propose contact using telemedicine tools or visiting the ofce 
in order to obtain support in difcult situations
ź offer education about changes in eating habits and physical activity 
through tele-visit or ofce visits
ź propose pharmacotherapy: as a rst-line drug, order a combined 
®product containing bupropion and naltrexone (Mysimba ); 
in case of contraindications, consider using the second-line drug 
®liraglutide at a dose of 3 mg (Saxenda ) — see the wording 
of the recommendation
ź recommend using the application to monitor food consumption 
and the level of physical activity
ź recommend using the application to monitor food consumption 
and the level of physical activity
ź propose contact using telemedicine tools in order to obtain support 
in difcult situations
ź monitor the patient’s body mass once every three months 
and react in the event of changes, assessing the intensity of eating 
under the inuence of emotions and whether or not eating 
disturbances develop
2
ź if the BMI is ≥ 25 kg/m , take a history of obesity complications
or, if necessary, order a diagnosis (their list is attached 
to the algorithm)
ź make a diagnosis based on the recommendations 
of the American Endocrine Societies
ź diagnose eating under the inuence of emotions (see the questions 
in the appendix) and eating disorders (diagnostic criteria in the 
appendix to the algorithm) and depressed mood (Beck’s scale)
Ofce visit
Establish partial and long-term treatment goals
(see recommendation text)
Choose treatment methods individually:
Choose treatment methods individually:
Teleadvice
Ask the patient to weigh him/herself, give his/her weight and
height, and calculate BMI:
You recognise overweight or obesity and/or under the inuence
of emotional eating or eating disturbances
Monitor the effects of treatment and follow 
the recommendations at least once a month
The minimum duration of pharmacotherapy is 6 months
If necessary, pharmacotherapy can be resumed after a break
If necessary, enable patient contact using telemedicine tools
ź consider continuing 
pharmacotherapy 
– recommend control visits 
every 3 months
ź if necessary, enable patient 
contact using telemedicine 
tools
ź the use of pharmacotherapy 
supporting obesity treatment, 
as a rst-line drug, order 
a combined product 
containing bupropion 
®
and naltrexone (Mysimba ); 
in case of contraindications, 
consider the use of the 
second-line drug liraglutide 
®at a dose of 3 mg (Saxenda ) 
— see the recommendation
ź continue supporting 
the patient through 
telemedicine or during 
ofce visits
ź continue observation
ź continue supporting 
the patient through 
telemedicine or during 
ofce visits
ź recommend that the patient 
continue using the application 
for monitoring food 
consumption and the level 
of physical activity
ź verify the patient’s 
compliance with the 
recommendations, including 
those regarding the use 
of pharmacotherapy – check 
data from applications used 
by the patient
ź recommend more frequent 
contact using telemedicine 
tools – propose 
psychotherapy if it has not 
been used so far
You have not recognised obesity or overweight, but there is
a tendency to eat emotionally without eating disturbances
Partial and long-term 
therapeutic goal achieved:
If there was a body mass gain 
of more than 3% of the initial 
or eating disturbances
development, consider:
No change in body mass:
Partial goal has not been
achieved:
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We hope that it will be a helpful tool to facilitate 
everyday work and will result in more patients being 
properly diagnosed and effectively treated.
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